Human Preosteoblastic Cell Culture from a Patient with Severe Tumoral Calcinosis-Hyperphosphatemia Due to a New GALNT3 Gene Mutation: Study of In Vitro Mineralization

[1]  Chunlin Li,et al.  Association of GALNT3 gene polymorphisms with bone mineral density in Chinese postmenopausal women: the Peking Vertebral Fracture study , 2014, Menopause.

[2]  M. Vervloet,et al.  Laboratory aspects of circulating α-Klotho. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  W. Richards,et al.  Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit Mineralization , 2011, Calcified Tissue International.

[4]  Steve D. M. Brown,et al.  Genome-Wide Association Study Using Extreme Truncate Selection Identifies Novel Genes Affecting Bone Mineral Density and Fracture Risk , 2011, PLoS genetics.

[5]  E. Sprecher,et al.  Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis , 2011, Journal of Bone and Mineral Metabolism.

[6]  M. Econs,et al.  Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. , 2010, Biochemical and biophysical research communications.

[7]  Leah R. Padgett,et al.  Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations , 2010, American journal of medical genetics. Part A.

[8]  M. Kuro-o.  A potential link between phosphate and aging—Lessons from Klotho-deficient mice , 2010, Mechanisms of Ageing and Development.

[9]  H. Jüppner,et al.  Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis. , 2009, The Journal of clinical endocrinology and metabolism.

[10]  E. Sprecher,et al.  Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis. , 2009, Biochimica et biophysica acta.

[11]  T. A. Fritz,et al.  Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. , 2009, Endocrinology.

[12]  D. Campanacci,et al.  A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis. , 2009, The Journal of bone and joint surgery. American volume.

[13]  Y. Nabeshima.  Discovery of α-Klotho unveiled new insights into calcium and phosphate homeostasis , 2009, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[14]  J. Uitto,et al.  GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity. , 2009, Biochimica et biophysica acta.

[15]  E. Farrow,et al.  A case of familial tumoral calcinosis/hyperostosis–hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features , 2009, Osteoporosis International.

[16]  M. Razzaque,et al.  Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? , 2008, Kidney international.

[17]  Tijana Krajisnik,et al.  A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. , 2008, European journal of endocrinology.

[18]  Roberto Zonefrati,et al.  In vitro differentiation of human mesenchymal stem cells on Ti6Al4V surfaces. , 2008, Biomaterials.

[19]  S. Lepreux,et al.  Tumoral calcinosis due to GALNT3 C.516-2A >T mutation in a black African family. , 2008, Genetic counseling.

[20]  K. White,et al.  Two novel GALNT3 mutations in familial tumoral calcinosis , 2007, American journal of medical genetics. Part A.

[21]  M. Razzaque,et al.  Mineral metabolism and aging: the fibroblast growth factor 23 enigma , 2007, Current opinion in nephrology and hypertension.

[22]  M. Econs,et al.  Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. , 2007, The Journal of clinical endocrinology and metabolism.

[23]  P. Beck‐Peccoz,et al.  Two novel nonsense mutations in GALNT3 gene are responsible for familial tumoral calcinosis , 2007, Journal of Human Genetics.

[24]  K. White,et al.  A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. , 2007, The Journal of clinical investigation.

[25]  K. Okawa,et al.  Klotho converts canonical FGF receptor into a specific receptor for FGF23 , 2006, Nature.

[26]  M. Econs,et al.  Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. , 2006, The Journal of clinical endocrinology and metabolism.

[27]  T. Strom,et al.  Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis , 2006, Journal of Biological Chemistry.

[28]  F. S. Chew,et al.  Tumoral calcinosis: pearls, polemics, and alternative possibilities. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[29]  Jason R. Stubbs,et al.  Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. , 2006, Journal of the American Society of Nephrology : JASN.

[30]  I. Dianzani,et al.  Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family , 2006, Journal of Clinical Pathology.

[31]  M. Indelman,et al.  Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred , 2006, Journal of Human Genetics.

[32]  外山 隆介.  Impaired regulation of gonadotropins leads to the atrophy of the female reproductive system in klotho-deficient mice , 2006 .

[33]  Y. Takeuchi,et al.  A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. , 2005, The Journal of clinical endocrinology and metabolism.

[34]  M. Indelman,et al.  A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification , 2005, Human Genetics.

[35]  R. Bergman,et al.  Absence of Intraepidermal Glycosyltransferase ppGalNac-T3 Expression in Familial Tumoral Calcinosis , 2005, The American Journal of dermatopathology.

[36]  K. White,et al.  Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. , 2005, Bone.

[37]  S. Mooney,et al.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. , 2005, The Journal of clinical endocrinology and metabolism.

[38]  M. Econs,et al.  A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. , 2005, The Journal of clinical endocrinology and metabolism.

[39]  P. Orlik,et al.  An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. , 2005, Human molecular genetics.

[40]  D. Behar,et al.  Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders , 2005, Journal of Molecular Medicine.

[41]  D. Behar,et al.  Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders , 2005, Journal of Molecular Medicine.

[42]  R. Mason,et al.  Bone as a source of FGF23: regulation by phosphate? , 2004, Bone.

[43]  M. Razzaque,et al.  Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. , 2004, Matrix biology : journal of the International Society for Matrix Biology.

[44]  D. Behar,et al.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis , 2004, Nature Genetics.

[45]  Y. Takeuchi,et al.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. , 2004, The Journal of clinical investigation.

[46]  E. Montgomery,et al.  Most Osteomalacia-associated Mesenchymal Tumors Are a Single Histopathologic Entity: An Analysis of 32 Cases and a Comprehensive Review of the Literature , 2004, The American journal of surgical pathology.

[47]  K. Fukuda,et al.  Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. , 2003, Molecular endocrinology.

[48]  S. Gonnelli,et al.  Validation of a food frequency questionnaire for nutritional calcium intake assessment in Italian women , 2002, European Journal of Clinical Nutrition.

[49]  N. Itoh,et al.  Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. , 2000, Biochemical and biophysical research communications.

[50]  R. B. Payne,et al.  Calculation of renal tubular reabsorption of phosphate: the algorithm performs better than the nomogram , 2000, Annals of clinical biochemistry.

[51]  Tadashi Kaname,et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing , 1997, Nature.

[52]  P. Hauschka,et al.  Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. , 1996, The Biochemical journal.

[53]  W. R. Lee,et al.  Ocular tumoral calcinosis. A clinicopathologic study. , 1996, Archives of ophthalmology.

[54]  O. Bijvoet,et al.  NOMOGRAM FOR DERIVATION OF RENAL THRESHOLD PHOSPHATE CONCENTRATION , 1975, The Lancet.

[55]  Ralph,et al.  A Clinicopathologic Study , 2006 .